Cargando…

Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature Review

SIMPLE SUMMARY: Immune checkpoint inhibitors (ICIs) can cause granulomatous and sarcoid-like lesions (GSLs) in several organs, and limited data existing that adequately inform the incidence and severity. This study examined GSL incidence in patients with high-risk melanoma treated with CTLA4 or PD1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eljilany, Islam, Noor, Arish, Paravathaneni, Mahati, Yassine, Ibrahim, Lee, Sandra J., Othus, Megan, Moon, James, Kirkwood, John M., Sondak, Vernon K., Ribas, Antoni, Grossmann, Kenneth F., Tarhini, Ahmad A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177189/ https://www.ncbi.nlm.nih.gov/pubmed/37174027 http://dx.doi.org/10.3390/cancers15092561

Ejemplares similares

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
por: Tarhini, Ahmad A, et al.
Publicado: (2021)

Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis
por: Zarnegar-Lumley, Sara, et al.
Publicado: (2023)

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)
por: Wagner, Michael J, et al.
Publicado: (2021)

Phase II Trial of Sorafenib in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma: SWOG S0512
por: Bhatia, Shailender, et al.
Publicado: (2012)

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134
por: Atkins, Michael B., et al.
Publicado: (2023)

ECOG-ACRIN 2399: analysis of patient related outcomes after Chemoradiation for locally advanced head and neck Cancer
por: Cmelak, Anthony, et al.
Publicado: (2020)

Treatment of sarcoid granulomatous interstitial nephritis with adalimumab
por: Gupta, Roopali, et al.
Publicado: (2009)

MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603
por: Villaruz, Liza C., et al.
Publicado: (2015)

CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials
por: Ganzel, Chezi, et al.
Publicado: (2021)

Granulomatous Pancreas: A Case Report of Pancreatic Sarcoid
por: Bihun, Tatiana, et al.
Publicado: (2017)

Necrotising sarcoid granulomatosis. A rare granulomatous disease
por: Doubková, Martina, et al.
Publicado: (2018)

Sarcoidal granulomatous reaction to microneedling with vitamin C serum
por: Handal, Marina, et al.
Publicado: (2023)

Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOG‐ACRIN E2805 trial
por: Murphy, Caitlin C., et al.
Publicado: (2021)

Sarcoidal granulomatous reaction due to tattoos: report of two cases
por: Valbuena, Martha Cecilia, et al.
Publicado: (2017)

Sarcoid-like Granulomatous Lung Disease with Subacute Progression in Silicosis
por: Mochizuka, Yasutaka, et al.
Publicado: (2021)

Tozinameran: Cutaneous sarcoid-like granulomatous reaction: case report
Publicado: (2022)

Intimal granulomatous angiitis in sarcoid pulmonary vasculitis: worth remembering
por: Bernaudin, Jean-François, et al.
Publicado: (2023)

Impact of African ancestry on the relationship between body mass index and survival in an early‐stage breast cancer trial (ECOG‐ACRIN E5103)
por: Ballinger, Tarah J., et al.
Publicado: (2022)

Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial
por: Stockton, Shannon, et al.
Publicado: (2023)

Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198)
por: Schneider, Bryan P, et al.
Publicado: (2015)

Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era
por: King, Rebecca L., et al.
Publicado: (2018)

Phase II Trial of Eribulin in Patients With Metastatic Hormone Refractory Prostate Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E5805)
por: Stein, Mark N., et al.
Publicado: (2019)

A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG‐ACRIN Cancer Research Group (EAQ152)
por: Bradbury, Angela R., et al.
Publicado: (2021)

Pembrolizumab‐induced sarcoid granulomatous panniculitis and bullous pemphigoid in a single patient
por: Honigman, Anthony D., et al.
Publicado: (2019)

Sarcoid-like Granulomatous Intraocular Inflammation Caused by Vemurafenib Treatment for Metastatic Melanoma
por: Eser Öztürk, Hilal, et al.
Publicado: (2020)

Sarcoid Here, Sarcoid There, Sarcoid Everywhere
por: Iskander, Peter A, et al.
Publicado: (2023)

Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group’s clinical trial E3999
por: Rapaport, Franck, et al.
Publicado: (2022)

Sarcoid‐resembling granulomatous lung disease secondary to occupational magnetite iron dust exposure
por: Xiao, Lewis, et al.
Publicado: (2018)

A case of interstitial granulomatous dermatitis presenting in a patient with necrotizing sarcoid granulomatosis
por: Elsanadi, Rachel, et al.
Publicado: (2023)

Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies
por: Rakovitch, E., et al.
Publicado: (2018)

Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2
por: Wisinski, Kari B., et al.
Publicado: (2023)

Correction: Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group’s clinical trial E3999
por: Rapaport, Franck, et al.
Publicado: (2023)

Validation of brief symptom indexes among patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A trial of the ECOG‐ACRIN Cancer Research Group (E1302)
por: Oswald, Laura B., et al.
Publicado: (2020)

Patient-Reported Testing Burden of Breast Magnetic Resonance Imaging Among Women With Ductal Carcinoma In Situ: An Ancillary Study of the ECOG-ACRIN Cancer Research Group (E4112)
por: Fazeli, Soudabeh, et al.
Publicado: (2021)

Association Between Surgery Preference and Receipt in Ductal Carcinoma In Situ After Breast Magnetic Resonance Imaging: An Ancillary Study of the ECOG-ACRIN Cancer Research Group (E4112)
por: Fazeli, Soudabeh, et al.
Publicado: (2022)

Impact of Alternate b-Value Combinations and Metrics on the Predictive Performance and Repeatability of Diffusion-Weighted MRI in Breast Cancer Treatment: Results from the ECOG-ACRIN A6698 Trial
por: Partridge, Savannah C., et al.
Publicado: (2022)

Phase III Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection for Colon Cancer: An Intergroup Trial of the ECOG-ACRIN Cancer Research Group (E1292)
por: Kemeny, M. Margaret, et al.
Publicado: (2022)

HAM56 and CD68 antigen presenting cells surrounding a sarcoidal granulomatous tattoo
por: Velez, Ana Maria Abreu, et al.
Publicado: (2011)

The witches' advocate. Basque witchcraft and the Spanish Inquisition (1609–1614)
por: Walker, D. P.
Publicado: (1982)

Complete Genome Sequence of Agrobacterium tumefaciens 1D1609
por: Haryono, Mindia, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8slgflufaaectm1ch1pt4di5cj